Author Correction: Stem cell architecture drives myelodysplastic syndrome progression and predicts response to venetoclax-based therapy (Nature Medicine, (2022), 28, 3, (557-567), 10.1038/s41591-022-01696-4)
- Ganan-Gomez I.
- Yang H.
- Ma F.
- Montalban-Bravo G.
- Thongon N.
- Marchica V.
- Richard-Carpentier G.
- Chien K.
- Manyam G.
- Wang F.
- Alfonso A.
- Chen S.
- Class C.
- Kanagal-Shamanna R.
- Ingram J. P.
- Ogoti Y.
- Rose A.
- Loghavi S.
- Lockyer P.
- Cambo B.
- Muftuoglu M.
- Schneider S.
- Adema V.
- McLellan M.
- Garza J.
- Marchesini M.
- Giuliani N.
- Pellegrini M.
- Wang J.
- Walker J.
- Li Z.
- Takahashi K.
- Leverson J. D.
- Bueso-Ramos C.
- Andreeff M.
- Clise-Dwyer K.
- Garcia-Manero G.
- Colla S.
Publication date
January 2022
DOI Publisher
Springer Science and Business Media LLCAbstract
In the version of this article initially published, the name of the Edward P. Evans Foundation was shown incorrectly in the first sentence of the Acknowledgements. The name has been corrected in the HTML and PDF versions of the paper
Add to ORKG